Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Similar articles for PubMed (Select 11544910)

1.

[Vinorelbine in patients with malignant pleural mesothelioma--a phase II study].

Ost E, Illiger HJ.

Strahlenther Onkol. 2001 Aug;177(8):440-1. German. No abstract available.

PMID:
11544910
2.

Phase II study of vinorelbine in patients with malignant pleural mesothelioma.

Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM.

J Clin Oncol. 2000 Dec 1;18(23):3912-7.

PMID:
11099320
3.

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.

Stebbing J, Powles T, McPherson K, Shamash J, Wells P, Sheaff MT, Slater S, Rudd RM, Fennell D, Steele JP.

Lung Cancer. 2009 Jan;63(1):94-7. doi: 10.1016/j.lungcan.2008.04.001. Epub 2008 May 16.

PMID:
18486273
4.

Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma.

Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ, Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK, Khokhar AR, Shin DM.

J Clin Oncol. 2005 May 20;23(15):3495-501.

5.

Staging and evaluating responses in malignant pleural mesothelioma.

Hillerdal G.

Lung Cancer. 2004 Jan;43(1):75-6. No abstract available.

PMID:
14698540
6.

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK; Pemetrexed expanded access program investigators.

J Thorac Oncol. 2006 Jul;1(6):506-12. Erratum in: J Thorac Oncol. 2006 Sep;1(7):621.

PMID:
17409909
7.

Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).

Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M.

Ann Oncol. 2008 Feb;19(2):370-3. Epub 2007 Dec 20.

8.

Chemotherapy for malignant pleural mesothelioma.

Tomek S, Manegold C.

Curr Opin Oncol. 2003 Mar;15(2):148-56. Review.

PMID:
12601280
9.

Vindesine in the treatment of malignant mesothelioma: a phase II study.

Kelsen D, Gralla R, Cheng E, Martini N.

Cancer Treat Rep. 1983 Sep;67(9):821-2.

PMID:
6883358
10.

Phase II trial of pralatrexate (10-propargyl-10-deazaaminopterin, PDX) in patients with unresectable malignant pleural mesothelioma.

Krug LM, Heelan RT, Kris MG, Venkatraman E, Sirotnak FM.

J Thorac Oncol. 2007 Apr;2(4):317-20.

PMID:
17409804
11.

Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation.

Hollen PJ, Gralla RJ, Liepa AM, Symanowski JT, Rusthoven JJ.

Cancer. 2004 Aug 1;101(3):587-95.

12.

Malignant pleural and peritoneal mesothelioma: incidental diagnosis and excellent treatment results.

Miliauskas S, Zemaitis M, Pranys D.

J Thorac Oncol. 2009 Mar;4(3):435-6. doi: 10.1097/JTO.0b013e3181989551. No abstract available.

PMID:
19247093
13.

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P.

J Clin Oncol. 2003 Jul 15;21(14):2636-44.

PMID:
12860938
14.

MVP and vinorelbine for malignant pleural mesothelioma.

Mordant P, Loriot Y, Soria JC, Deutsch E.

Lancet. 2008 Aug 23;372(9639):629; author reply 629-30. doi: 10.1016/S0140-6736(08)61273-8. No abstract available.

PMID:
18722865
15.

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.

van den Bogaert DP, Pouw EM, van Wijhe G, Vernhout RM, Surmont VF, Hoogsteden HC, van Klaveren RJ.

J Thorac Oncol. 2006 Jan;1(1):25-30.

PMID:
17409823
16.

Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?

Rusch VW.

J Clin Oncol. 2003 Jul 15;21(14):2629-30. No abstract available.

PMID:
12860935
17.

Minimum Clinical Recommendations for diagnosis, treatment and follow-up of malignant pleural mesothelioma.

Manegold C, Stahel RA; ESMO Guidelines Task Force.

Ann Oncol. 2005;16 Suppl 1:i32-3. No abstract available.

18.

Phase II study of vinflunine in malignant pleural mesothelioma.

Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, Cadic V, Pinel MC, Rivière A, Ollivier L, Ruffié P.

J Clin Oncol. 2007 Oct 20;25(30):4751-6.

19.

Phase II trials in mesothelioma: an increasing challenge.

Nowak AK.

Lung Cancer. 2005 Oct;50(1):87-90. No abstract available.

PMID:
16026892
20.

Oxaliplatin and raltitrexed in the treatment of inoperable malignant pleural mesothelioma: results of a pilot study.

Maisano R, Caristi N, Toscano G, Aragona M, Spadaro P, Amadio P, Mare M, Zavettieri M, La Torre F.

Tumori. 2001 Nov-Dec;87(6):391-3.

PMID:
11989592
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk